Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice.

AVEO Pharmaceuticals, Cambridge, MA 02139. Novartis Institute for Biomedical Research, Cambridge, MA 02139. Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229-3039. Independent Consultant, Gettysburg, PA 17325. Independent Consultant, Natick, MA 01760. To whom correspondence should be addressed at Biologics Research and Development, Genzyme Corporation, 5 Mountain Road, Framingham, MA 01701-9322. Fax: (508) 661-1854. E-mail: laura.andrews@genzyme.com.